The anti-malarial chloroquine overcomes Primary resistance and restores sensitivity to Trastuzumab in HER2-positive breast cancer

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Cufí, Sílvia ^a,b   Vazquez Martin, Alejandro ^a,b   Oliveras Ferraros, Cristina ^a,b   Corominas Faja, Bruna ^a,b   Cuyàs, Elisabet ^a,b   López Bonet, Eugeni ^b,c   Martin Castillo, Begoña ^a,b   Joven, Jorge ^d   Menendez, Javier A ^a,b  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^c HOSPITAL JOSEP TRUETA   (Spain)

^d INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; CASPASE 3; CHLOROQUINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ANIMAL; ARTICLE; AUTOPHAGY; BREAST TUMOR; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; ENZYME ACTIVATION; FEMALE; GENETICS; HUMAN; METABOLISM; MOUSE; PATHOLOGY; PHAGOSOME; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIMALARIALS; ANTINEOPLASTIC AGENTS; AUTOPHAGY; BREAST NEOPLASMS; CASPASE 3; CELL LINE, TUMOR; CHLOROQUINE; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FEMALE; HUMANS; MICE; PHAGOSOMES; RECEPTOR, ERBB-2; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84883196778     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep02469     Document Type: Article

References (61)

1. Chong, C. R. & Sullivan, D. J. Jr. New uses for old drugs. Nature 448, 645-646 (2007). (Pubitemid 47236844)
2. Ashburn, T. T. & Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3, 673-683 (2004). (Pubitemid 39173508)
3. Reichert, J. M. Trends in development and approval times for new therapeutics in the United States. Nat Rev Drug Discov 2, 695-702 (2003). (Pubitemid 37361785)
4. Wiesner, J., Ortmann, R., Jomaa, H. & Schlitzer, M. New antimalarial drugs. Angew Chem Int Ed Engl 42, 5274-5293 (2003). (Pubitemid 37462636)
5. Breckenridge, A. M. &Winstanley, P. A. Clinical pharmacology and malaria. Ann Trop Med Parasitol 91, 727-733 (1997). (Pubitemid 27480438)
6. Solomon, V. R. & Lee, H. Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur J Pharmacol 625, 220-233 (2009).
7. He, C. & Klionsky, D. J. Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet 43, 67-93 (2009).
8. Klionsky, D. J. & Emr, S. D. Autophagy as a regulated pathway of cellular degradation. Science 290, 1717-1721 (2000). (Pubitemid 32004796)
9. Tanida, I. Autophagosome formation and molecular mechanism of autophagy. Antioxid Redox Signal 14, 2201-2214 (2011).
10. Pyo, J. O., Nah, J. & Jung, Y. K. Molecules and their functions in autophagy. Exp Mol Med 44, 73-80 (2012).
11. Yang, Z. J., Chee, C. E., Huang, S. & Sinicrope, F. A. The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther 10, 1533-1541 (2011).
12. Giansanti, V. et al. Killing of tumor cells: a drama in two acts. Biochem Pharmacol 82, 1304-1310 (2011).
13. Janku, F., McConkey, D. J., Hong, D. S. & Kurzrock, R. Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol 8, 528-539 (2011).
14. Amaravadi, R. K. et al. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 17, 654-666 (2011).
15. Mancias, J. D. & Kimmelman, A. C. Targeting autophagy addiction in cancer. Oncotarget 2, 1302-1306 (2011).
16. Boya, P. et al. Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol 25, 1025-1040 (2005). (Pubitemid 40165810)
17. Hu, C., Solomon, V. R., Ulibarri, G. & Lee, H. The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine. Bioorg Med Chem 16, 7888-7893 (2008).
18. Jiang, P. D. et al. Antitumor and antimetastatic activities of chloroquine diphosphate in a murine model of breast cancer. Biomed Pharmacother 64, 609-614 (2010).
19. Degtyarev,M. et al. Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. J Cell Biol 183, 101-116 (2008).
20. Fan, Q. W. et al. Akt and autophagy cooperate to promote survival of drugresistant glioma. Sci Signal 3, ra81 (2010).
21. Maycotte, P. et al. Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy. Autophagy 8, 200-212 (2012).
22. Gorski, S. M., Ries, J. & Lum, J. J. Targeting autophagy: The Achilles' heel of cancer. Autophagy 8, 1279-1280 (2012).
23. McAfee, Q. et al. Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. Proc Natl Acad Sci USA 109, 8253-8258 (2012).
24. Amaravadi, R. K. & Winkler, J. D. Lys05: A new lysosomal autophagy inhibitor. Autophagy 8, 1383-1384 (2012).
25. Liu, J. et al. Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell 147, 223-234 (2011).
26. Tanner, M. et al. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther 3, 1585-1592 (2004). (Pubitemid 40136714)
27. Nagy, P. et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 65, 473-482 (2005).
28. Köninki, K. et al. Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells. Cancer Lett 294, 211-219 (2010).
29. Vazquez-Martin, A., Oliveras-Ferraros, C., Del Barco, S., Martin-Castillo, B. & Menendez, J. A. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Res Treat 126, 355-364 (2011).
30. Damiano, V. et al. A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action. Clin Cancer Res 15, 6921-6930 (2009).
31. Oliveras-Ferraros, C. et al. Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin). Biochem Biophys Res Commun 397, 27-33 (2010).
32. Oliveras-Ferraros, C. et al. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin). Int J Oncol 37, 669-678 (2010).
33. Valabrega, G. et al. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. Breast Cancer Res Treat 130, 29-40 (2011).
34. Oliveras-Ferraros, C. et al. Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies. Biochem Biophys Res Commun 407, 412-419 (2011).
35. Cufi, S. et al. Metformin-induced preferential killing of breast cancer initiating CD441CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER21 human breast cancer xenografts. Oncotarget 3, 395-398 (2012).
36. Oliveras-Ferraros, C. et al. Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin). Cell Cycle 11, 4020-4032 (2012).
37. Barok, M. et al. Trastuzumab causes antibody-dependent cellular cytotoxicitymediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther 6, 2065-2072 (2007). (Pubitemid 47052497)
38. Ahtiainen, L. et al. Defects in innate immunity render breast cancer initiating cells permissive to oncolytic adenovirus. PLoS One 5, e13859 (2010).
39. Rubinsztein, D. C., Gestwicki, J. E., Murphy, L. O. & Klionsky, D. J. Potential therapeutic applications of autophagy. Nat Rev Drug Discov 6, 304-312 (2007). (Pubitemid 46505881)
40. Mizushima, N., Yoshimori, T. & Levine, B. Methods in mammalian autophagy Research. Cell 140, 313-326 (2010).
41. Klionsky, D. J. et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8, 445-544 (2012).
42. Sarkar, S., Davies, J. E., Huang, Z., Tunnacliffe, A. & Rubinsztein, D. C. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J Biol Chem 282, 5641-5652 (2007). (Pubitemid 47093730)
43. Cuf?́, S. et al. Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: Utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment. Oncotarget 3, 1600-1614 (2012).
44. Vazquez-Martin, A., Oliveras-Ferraros, C. & Menendez, J. A. Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab. PLoS One 4, e6251 (2009).
45. Bjørkøy, G. et al. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol 171, 603-614 (2005). (Pubitemid 41668720)
46. Bjørkøy, G., Lamark, T. & Johansen, T. p62/SQSTM1: a missing link between protein aggregates and the autophagy machinery. Autophagy 2, 138-139 (2006).
47. Pankiv, S. et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem 282, 24131-24145 (2007). (Pubitemid 47328003)
48. Ichimura, Y., Kominami, E., Tanaka, K. & Komatsu, M. Selective turnover of p62/A170/SQSTM1 by autophagy. Autophagy 4, 1063-1066 (2008).
49. Shvets, E. & Elazar, Z. Autophagy-independent incorporation of GFP-LC3 into protein aggregates is dependent on its interaction with p62/SQSTM1. Autophagy 4, 1054-1056 (2008).
50. Yorimitsu, T. & Klionsky, D. J. Autophagy: molecular machinery for self-eating. Cell Death Differ 12, 1542-1552 (2005). (Pubitemid 41553991)
51. Xie, Z. & Klionsky, D. J. Autophagosome formation: core machinery and adaptations. Nat Cell Biol 9, 1102-1109 (2007). (Pubitemid 47500484)
52. Geng, J. & Klionsky, D. J. The Atg8 and Atg12 ubiquitin-like conjugation systems in macroautophagy. 'Protein modifications: beyond the usual suspects' review series. EMBO Rep 9, 859-864 (2008).
53. Mizushima, N., Yoshimori, T. & Ohsumi, Y. The role of Atg proteins in autophagosome formation. Annu Rev Cell Dev Biol 27, 107-132 (2011).
54. Cuf?́, S., Vazquez-Martin, A., Oliveras-Ferraros, C.,Martin-Castillo, B., Vellon, L. & Menendez, J. A. Autophagy positively regulates the CD44(1) CD24(-/low) breast cancer stem-like phenotype. Cell Cycle 10, 3871-3885 (2011).
55. Degtyarev, M. et al. Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. J Cell Biol 183, 101-116 (2008).
56. Fan, Q. W. et al. Akt and autophagy cooperate to promote survival of drugresistant glioma. Sci Signal 3, ra81 (2010).
57. Hanahan, D.&Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
58. Ward, P. S.&Thompson, C. B.Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 21, 297-308 (2012).
59. Cheng, Y., Li, H., Ren, X., Niu, T., Hait, W. N. & Yang, J. Cytoprotective effect of the elongation factor-2 kinase-mediated autophagy in breast cancer cells subjected to growth factor inhibition. PLoS One 5, e9715 (2010).
60. Huang, H. L. et al. Lapatinib induces autophagy, apoptosis and megakaryocytic differentiation in chronic myelogenous leukemia K562 cells. PLoS One 6, e29014 (2011).
61. Han, W. et al. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS One 6, e18691 (2011).